Opinion|Videos|April 3, 2025
Checkpoint Inhibitors for Treatment of NMIBC
Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive patients with non–muscle-invasive bladder cancer (NMIBC).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In addition to recent approval, several immunotherapies such as PD-(L)-1 inhibitors (durvalumab and sasanlimab) are being evaluated in BCG-unresponsive patients. What are your initial impressions of available data with immunotherapies?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
2
Practical guide to female pelvic organ–sparing radical cystectomy
3
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
4
Targeting BCG resistance in high-risk NMIBC
5